Jazz Pharmaceuticals PLC (JAZZ)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.50B
Last updated: Nov 17, 2026 at 11:05 AM ET
Jazz Pharmaceuticals PLC (JAZZ) Stock Forecast
Analysts expect Jazz Pharmaceuticals (JAZZ) to earn $14.94 per share in the fiscal year ending Dec 31, 2026, on revenue of $4.80B. Of 22 analysts, 20 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 9 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 22 ratings average 1.77, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 91% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 7 | 31.8% |
| Buy | 13 | 59.1% |
| Hold | 2 | 9.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 22
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 73.9% and revenue estimates rise 5.4%.
- Fiscal year ending Dec 31, 2026
- $14.94
- EPS consensus, revenue $4.80B
- Fiscal year ending Dec 31, 2027
- $25.98
- EPS consensus, revenue $5.06B
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $14.94 | $13.98 to $15.97 | 19 | $4.80B | $4.75B to $4.84B | 20 |
| Dec 31, 2027 | $25.98 | $13.70 to $32.14 | 19 | $5.06B | $4.75B to $5.29B | 21 |
Quarterly Estimates
The EPS consensus falls from $7.12 for the quarter ending Dec 31, 2026 to $5.89 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $7.12 | $5.19 to $13.32 | 22 | $1.30B | $1.20B to $1.39B | 20 |
| Mar 31, 2027 | $5.89 | $4.88 to $6.70 | 6 | $1.14B | $1.12B to $1.17B | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 14 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 9 |
| Fiscal year ending Dec 31, 2027 | 5 | 5 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 40.3% from $25.03.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $14.94 | $15.49 | $16.12 | $24.39 | $25.03 | -40.3% |
| Fiscal year ending Dec 31, 2027 | $25.98 | $25.20 | $24.02 | $25.08 | $25.77 | +0.8% |
| Quarter ending Mar 31, 2027 | $5.89 | $6.26 | $5.65 | $5.65 | $5.64 | +4.4% |
Frequently Asked Questions About JAZZ
What is the JAZZ stock forecast?
Consensus analyst estimates put Jazz Pharmaceuticals's EPS at $14.94 for the fiscal year ending Dec 31, 2026, on revenue of $4.80B. The consensus rating from 22 analysts is Buy.
How do analysts rate JAZZ stock?
Of 22 analysts covering Jazz Pharmaceuticals, 7 rate it Strong Buy, 13 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from JAZZ next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $14.94, with estimates from $13.98 to $15.97 from 19 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $25.98, with estimates from $13.70 to $32.14 from 19 analysts.
What revenue do analysts expect from Jazz Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $4.80B, with estimates from $4.75B to $4.84B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $5.06B, with estimates from $4.75B to $5.29B.
How many analysts cover JAZZ?
22 analysts rate Jazz Pharmaceuticals stock, and 19 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
JAZZ pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts